MaxCyte (NASDAQ:MXCT) and Bullfrog AI (NASDAQ:BFRGW) Critical Analysis

MaxCyte (NASDAQ:MXCT) and Bullfrog AI (NASDAQ:BFRGW) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Earnings and Valuation

This table compares MaxCyte and Bullfrog AI”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03 million	4.28	-$44.63 million	($0.33)	-4.00
Bullfrog AI	$116,670.00	N/A	N/A	N/A	N/A

Bullfrog AI has lower revenue, but higher earnings than MaxCyte.

Institutional & Insider Ownership

68.8% of MaxCyte shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares MaxCyte and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.52%	-15.77%
Bullfrog AI	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for MaxCyte and Bullfrog AI, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1	0	1	0	2.00
Bullfrog AI	0	0	0	0	0.00

MaxCyte currently has a consensus price target of $5.00, suggesting a potential upside of 278.79%. Given MaxCyte’s stronger consensus rating and higher probable upside, equities research analysts plainly believe MaxCyte is more favorable than Bullfrog AI.

Summary

MaxCyte beats Bullfrog AI on 6 of the 9 factors compared between the two stocks.

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

About Bullfrog AI

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.